Marc Beer is the brains behind Renovia Inc., a pharmaceutical start-up that is dedicated to discovering and delivering products and technologies that help diagnose and treat various pelvic disorders in women. What has he achieved as the Chairman and CEO of Renovia? Has he helped Renovia achieve its goals? Well, read on to find out.
Why Marc Is A Blessing To Renovia Inc.
Under Marc Beer’s leadership, Renovia has transformed from an unknown start-up to a renowned commercial enterprise with rapid growth. The company has also been able to attract high-profile investors such as OSF Ventures, Longwood Fund, Nova Strategic Investments, Western Technology Investment, and Cormorant Asset Management. These financiers have invested more than $50 million in the Renovia. Learn more: https://www.slideshare.net/MarcBeer
Marc was also part of the team that came up with Renovia first product, Leva, which recently received approval from the FDA (Food and Drug Administration). He is also the man behind the team that is helping Renovia develop devices and treatments to fight urinary incontinence, which affects more 250 million women around the world.
Education And Career
Marc Beer went Miami University, Ohio, where he graduated with a degree in BS. After graduating, Marc joined the team at Abbott Laboratories, where he held a variety of sales and marketing roles. At Abbott, he helped the company come up with unique marketing strategies that made the pharmaceutical cement its market position and expand to new regions. After working for Abbott Laboratories for several years, Marc went on to join Genzyme. At Genzyme, he held various positions and was later appointed the Vice President of Global Marketing. As VP, Marc was responsible for the commercial launch of several products, devices, and treatments, which helped fight rare diseases around the world.
In April 2000, the exceptional scientist founded his first company, ViaCell. ViaCell is a biotechnology company that enables the use of human cells as medicine. The company also offers a service that allows families to preserve umbilical cord blood at the time of birth for possible future medical use. Amazing, right? Under Marc’s leadership, ViaCell moved from a lean startup to a force to reckon with in the biotechnology and pharmaceutical sector.
ViaCell continues to gain popularity and has created job opportunities for more than 300. In 2005, the company went public and raised more than $62 million from investors. In 2007, Marc sold ViaCell PerkinElmer in a deal that made him a millionaire. Marc has also served as a member of the Board of Directors of ERYP. He is also part of the team that came up with Good Start Genetics, where he serves as Chairman of the Board. He is also a dedicated member of Miami University Business Advisory Council.